


In Q3, 66% (54,175) of all reported TB cases were among males. The high proportion of male cases reported was similar across age brackets for adults, ranging from 70% among those 45 to 54 years and 55% for those less than 15 years (Figure 3). These data mirror the results from the 2016 National TB Prevalence Survey (NTPS) that reported a higher prevalence of TB among males and the need to address gender-related health barriers. There is also a need to screen women, as there might be missing diagnoses of women.


Only 9% of the reported cases were less than 15 years of age, yet the national target is that 12% of the total TB cases notified should be in children. It is imperative to improve TB detection and treatment for children less than 15 years of age to reach the PhilSTEP1 target through contact investigations and active TB screening for failure-to-thrive in under-five clinics that use growth charts.

Figure 3. Number of Notified TB Cases (All Forms) by Sex and Age Group, Q3 2019




Clinically-diagnosed (CD) cases accounted for 57% of the total TB cases notified. There was an increasing trend in bacteriologically-confirmed (BC) cases from Q1 to Q3. BC cases constituted 43% of all notified cases in Q3 — an increase of 5% from the Q2 performance (Figure 4). The increasing trend may be attributed to the scale-up of rapid molecular tests as the primary diagnostic tool.

Figure 4. Number of Notified TB Cases (All Forms) by Bacteriological Status, Q1 to Q3 2019




Eight regions have more than 45% of BC cases, with Region XI having the highest proportion (58%). Meanwhile, Region II had the lowest proportion with 37% of BC cases (Figure 5).

Figure 5. Proportion of Notified Cases (All Forms) by Bacteriological Status, Q3 2019



In Q3, 84% (71,562) of the TB cases were reported as new and 13% (10,716) were relapse (Figure 6). Relapse cases are cases that had previously been treated for TB and are considered cured or completed with the prescribed treatment regimen. Three percent (2,418) were “other” retreatment TB cases due to treatment failure, loss to follow-up, or unknown treatment outcome. In five regions more than 90% of TB cases are new, with CAR having the highest proportion of new cases (94%). Region VI and NCR had the highest percentage of relapse cases, with 17% and 16%, respectively.


Figure 6. Proportion of Notified TB Cases by Registration Group, Q3 2019



Drug-Resistant TB (DR-TB) Cases

In 2019, NTP targets are to notify 20,674 DR-TB cases. As of Q3, a total of only 2,765 (13%) had been reported (**Figure 7**).

Figure 7. Notified DR-TB Cases, Q1 to Q3 2019



Note: Q3 cumulative accomplishment compared to the annual target at the national level.

In Q3, there were 1,195 DR-TB cases detected nationwide, which is <2% of all TB cases notified (**Table 3**). The highest number was found in NCR, followed by Regions III, IV, and VI. The majority of the regions increased DR-TB case finding in Q3, with NCR having the most progress by achieving 47% of its target, while CAR decreased performance from Q2 to Q3 (**Table 4**). Low performance in DR-TB detection may be caused by limited availability and uptake of rapid diagnostic tests (RDTs) for TB, such as Xpert MTB/RIF, at the point of service. NTP should ensure access to an adequate supply of RDTs, assess its uptake, and ensure increased utilization of tests following the national criteria for testing. Targets can be achieved by (1) using rapid molecular tests as primary diagnostics, including in the private sector and (2) systematic screening to find the missing TB patients of all types.

Table 3. Notified DR-TB Cases by Region, Q3 2019

Region	Target (Q3)	DR-TB Cases Notified (Q3)	%
National	5,169	1,195	23%
NCR	629	296	47%
III	561	160	29%
IV	725	197	27%
VI	389	104	27%
I	257	65	25%
MIMAROPA	160	36	23%
V	311	68	22%
XIII	141	27	19%
XII	237	37	16%
II	176	27	15%
VII	379	54	14%
VIII	233	32	14%
IX	193	26	13%
XI	255	31	12%
X	239	19	8%
BARMM	196	12	6%
CAR	92	4	4%

Figure 8. DR-TB Case Notification by Region, Q3 2019





Table 4. Percentage of Targets Achieved for Notified DR-TB Cases by Region, Q1 to Q3 2019 Comparison

Q1		Q2		Q3	
National	12%	National	19%	National	23%
NCR	25%	NCR	37%	NCR	47%
I	17%	III	29%	III	29%
IV	15%	MIMAROPA	25%	IV	27%
V	15%	I	20%	VI	27%
MIMAROPA	14%	VI	20%	I	25%
III	11%	IV	19%	MIMAROPA	23%
VI	10%	V	17%	V	22%
VIII	10%	XIII	16%	XIII	19%
XIII	9%	VIII	12%	XII	16%
IX	8%	XII	11%	II	15%
VII	7%	II	10%	VII	14%
XI	7%	VII	10%	VIII	14%
XII	6%	X	10%	IX	13%
CAR	4%	IX	9%	XI	12%
II	4%	XI	8%	X	8%
X	3%	CAR	7%	BARMM	6%
BARMM	2%	BARMM	5%	CAR	4%


In Q3, 73% (873) of all reported DR-TB cases were males (Figure 9). The gender distribution was similar across age brackets: 45 to 54 years old accounted for 42% of the total DR-TB cases reported.

Figure 9. Number of Notified DR-TB Cases by Sex and Age Group, Q3 2019



Of all DR-TB cases notified in Q3, 42% (790) were relapse TB cases (Figure 10). "Other" retreatment TB cases due to treatment failure, loss to follow-up, or unknown treatment outcome accounted for 33% (634), which was higher than the percentage of cases with no previous history of TB treatment (25% or 474 cases). Region V had the highest proportion of relapse cases (55%), Region X the highest proportion of other retreatment cases (46%), and CAR and Region II the highest proportion of new cases (43%) with DR-TB. NTP should continue to ensure correct and appropriate diagnosis and treatment for DR-TB and improve patient counseling and follow-up to increase patient treatment adherence.

Figure 10. Proportion of Notified DR-TB Cases by Registration Group, Q3 2019



Source: Department of Health – Integrated TB Information System (ITIS), accessed February 3, 2020



To access real-time patient-based information from facilities within the NTP network, visit the "TB Dashboard PH" [web dashboard](#). You may also download the "TB Dashboard PH" mobile apps via [App Store](#) or [Google Play Store](#).

National Tuberculosis Control Program
Department of Health
Room 103, Building 12, San Lazaro Compound, Rizal Avenue,
Sta. Cruz, Manila, Philippines 1003
+63 (02)-5310-5713/8230-9626
www.ntp.doh.gov.ph

